1. Home
  2. DENN vs CTNM Comparison

DENN vs CTNM Comparison

Compare DENN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Denny's Corporation

DENN

Denny's Corporation

HOLD

Current Price

$6.17

Market Cap

318.8M

ML Signal

HOLD

Logo Contineum Therapeutics Inc. Class A Common Stock

CTNM

Contineum Therapeutics Inc. Class A Common Stock

HOLD

Current Price

$11.04

Market Cap

328.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DENN
CTNM
Founded
1953
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
318.8M
328.1M
IPO Year
1989
2024

Fundamental Metrics

Financial Performance
Metric
DENN
CTNM
Price
$6.17
$11.04
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$5.45
$20.00
AVG Volume (30 Days)
2.7M
169.9K
Earning Date
11-03-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.20
N/A
Revenue
$457,212,000.00
N/A
Revenue This Year
$6.56
N/A
Revenue Next Year
$1.56
N/A
P/E Ratio
$31.51
N/A
Revenue Growth
0.93
N/A
52 Week Low
$2.85
$3.35
52 Week High
$7.66
$15.25

Technical Indicators

Market Signals
Indicator
DENN
CTNM
Relative Strength Index (RSI) 65.68 49.67
Support Level $6.13 $10.42
Resistance Level $6.20 $11.43
Average True Range (ATR) 0.02 0.80
MACD -0.04 -0.02
Stochastic Oscillator 64.29 28.10

Price Performance

Historical Comparison
DENN
CTNM

About DENN Denny's Corporation

Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: